# US 2003/0077645 A1 · Superfamily receptor chimeras, translocation assay for superfamily receptor ligands, and methods and kits for detecting and characterizing receptor ligands

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0077645 A1
- Document ID: US20030077645A1
- Status: Published application
- Kind: A1
- Application number: 10/259,864
- Filed: 2002-09-30
- Published: 2003-04-24
- Earliest claimed: 2001-09-28
- Inventors: Gordon L. Hager; Susan MacKem
- Web page: https://patentgrep.com/patent/US20030077645A1

## CPC

- G01N 33/6875: {Nucleoproteins}
- C07K 14/721: {Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor}
- C12N 15/1027: {by DNA shuffling, e.g. RSR, STEP, RPR}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/00: Fusion polypeptide
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to novel superfamily receptor chimeras, methods for using superfamily receptor chimeras, methods and kits for detecting cellular function and metabolic state, and the treatment of disease states involving defective receptor protein cytoplasm/nuclear translocation. In particular, this invention is preferably directed to chimeras of glucocorticoid receptor/superfamily receptor proteins.

## Claims

### Claim 1

A method for making a recombinant nuclear translocation protein, comprising:
covalently connecting (i) a glucocorticoid receptor DNA sequence coding for the cytoplasmic/nuclear translocation domain of the glucocorticoid receptor protein, (ii) a superfamily receptor DNA sequence coding for the ligand binding domain of a superfamily receptor protein, and (iii) a nucleic acid sequence for a marker protein domain, to form a DNA chimera,
wherein said superfamily receptor DNA sequence is connected to the 3′ end of said glucocorticoid receptor DNA sequence; and
expressing said DNA chimera in an expression system to prepare said protein.

### Claim 2 (depends on 1)

The method of claim 1, further comprising:
covalently connecting said translocation domain of the glucocorticoid receptor and said ligand binding domain of a superfamily receptor utilizing a DNA linker sequence.

### Claim 3 (depends on 2)

The method of claim 2, wherein said DNA linker sequence is a fragment of a polylinker sequence.

### Claim 4 (depends on 1)

The method of claim 1, wherein said marker protein domain DNA sequence is covalently connected to the 5′ end of said glucocorticoid receptor DNA sequence.

### Claim 5 (depends on 4)

The method of claim 4, further comprising:
covalently connecting said glucocorticoid receptor DNA sequence and said nucleic acid sequence for a marker protein utilizing a DNA linker sequence.

### Claim 6 (depends on 1)

The method of claim 1, wherein said glucocorticoid receptor DNA sequence encompasses the 5′ end of said sequence through and including the complete nuclear localization sequence of said glucocorticoid receptor DNA sequence.

### Claim 7 (depends on 1)

The method of claim 1, wherein said glucocorticoid receptor DNA sequence encompasses the 5′ end of said sequence through and including the complete nuclear localization sequence and the complete helix 1 sequence of said glucocorticoid receptor DNA sequence.

### Claim 8 (depends on 1)

The method of claim 1, wherein said glucocorticoid receptor DNA sequence encompasses the 5′ end of said sequence through and including DNA bases corresponding to about amino acid residue 570of said glucocorticoid receptor protein.

### Claim 9 (depends on 1)

The method of claim 1, wherein said superfamily receptor DNA sequence encompasses the 3′ end of said sequence through and including the complete ligand binding domain sequence and the complete helix 3 sequence of said superfamily receptor DNA sequence.

### Claim 10 (depends on 1)

The method of claim 1, wherein said superfamily receptor DNA sequence encompasses the 3′ end of said sequence through and including the complete ligand binding domain sequence, the complete helix 3 sequence, and at most a fragment of helix 1 of said superfamily receptor DNA sequence.

### Claim 11

A protein produced by the process of:
covalently connecting (i) a glucocorticoid receptor DNA sequence coding for the 5′ end of the DNA sequence of the glucocorticoid receptor protein, through and including the complete nuclear localization sequence and the complete helix 1 sequence of said glucocorticoid receptor DNA sequence, (ii) a superfamily receptor DNA sequence coding for the 3′ end of the DNA sequence of a superfamily receptor protein, through and including the complete ligand binding domain sequence and the complete helix 3 sequence of said superfamily receptor DNA sequence, and (iii) a nucleic acid sequence for a marker protein domain, to form a DNA chimera,
wherein said superfamily receptor DNA sequence is connected to the 3′ end of said glucocorticoid receptor DNA sequence,
wherein said marker protein domain DNA sequence is covalently connected to the 5′ end of said glucocorticoid receptor DNA sequence,
and wherein said translocation domain of the glucocorticoid receptor and said ligand binding domain of a superfamily receptor are covalently connected by a DNA linker sequence; and
expressing said DNA chimera in an expression system to prepare said protein.

### Claim 12

A nucleic acid chimera comprising:
a nucleic acid sequence which codes for the cytoplasmic/nuclear translocation domain of glucocorticoid receptor protein; and
a nucleic acid sequence which codes for the ligand binding domain of a superfamily receptor protein.

### Claim 13 (depends on 12)

The nucleic acid chimera of claim 12, additionally comprising:
a nucleic acid sequence for a marker protein domain.

### Claim 14 (depends on 13)

The nucleic acid chimera of claim 13, wherein said marker protein domain encodes a fluorescent protein.

### Claim 15 (depends on 12)

The nucleic acid chimera of claim 12, wherein said glucocorticoid receptor DNA sequence encompasses the 5′ end of said sequence through and including the complete nuclear localization sequence of said glucocorticoid receptor DNA sequence.

### Claim 16 (depends on 12)

The nucleic acid chimera of claim 12, wherein said glucocorticoid receptor DNA sequence encompasses the 5′ end of said sequence through and including the complete nuclear localization sequence and the complete helix 1 sequence of said glucocorticoid receptor DNA sequence.

### Claim 17 (depends on 12)

The nucleic acid chimera of claim 12, wherein said glucocorticoid receptor DNA sequence encompasses the 5′ end of said sequence through and including DNA bases corresponding to about amino acid residue 570of said glucocorticoid receptor protein.

### Claim 18 (depends on 12)

The nucleic acid chimera of claim 12, wherein said superfamily receptor DNA sequence encompasses the 3′ end of said sequence through and including the complete ligand binding domain sequence and the complete helix 3 sequence of said superfamily receptor DNA sequence.

### Claim 19 (depends on 12)

The nucleic acid chimera of claim 12, wherein said superfamily receptor DNA sequence encompasses the 3′ end of said sequence through and including the complete ligand binding domain sequence, the complete helix 3 sequence, and at most a fragment of helix 1 of said superfamily receptor DNA sequence.

### Claim 20 (depends on 12)

The nucleic acid chimera of claim 12, wherein said ligand binding domain is the ligand binding domain of estrogen receptor.

### Claim 21 (depends on 12)

The nucleic acid chimera of claim 12, which is SEQ. ID NO. 1.

### Claim 22 (depends on 12)

The nucleic acid chimera of claim 12, wherein said ligand binding domain is the ligand binding domain of retinoic acid receptor.

### Claim 23 (depends on 12)

The nucleic acid chimera of claim 12, which is SEQ. ID NO. 2.

### Claim 24

A chimeric protein comprising two elements:
a glucocorticoid receptor 5′ end, encompassing the nuclear translocation domain and helix 1; and
a superfamily receptor 3′ end, encompassing the ligand binding domain and helix 3.

### Claim 25 (depends on 24)

The chimeric protein of claim 24, further comprising a marker protein domain.

### Claim 26 (depends on 25)

The chimeric protein of claim 25, wherein said marker protein domain encodes a fluorescent protein.

### Claim 27 (depends on 24)

The chimeric protein of claim 24, wherein said ligand binding domain is the ligand binding domain of estrogen receptor.

### Claim 28 (depends on 24)

The chimeric protein of claim 24, which is SEQ. ID NO. 3.

### Claim 29 (depends on 24)

The chimeric protein of claim 24, wherein said ligand binding domain is the ligand binding domain of retinoic acid receptor.

### Claim 30 (depends on 24)

The chimeric protein of claim 24, which is SEQ. ID NO. 4.

### Claim 31

A method for detecting a ligand of a superfamily receptor protein, which comprises:
producing a nucleic acid vector encoding a nucleic acid chimera comprising three elements: a 5′ end of a glucocorticoid receptor, encompassing the nuclear translocation domain and helix 1, a 3′ end of a superfamily receptor, encompassing the ligand binding domain and helix 3, and a nucleic acid sequence for a marker protein domain;
transfecting a eukaryotic cell with said nucleic acid vector;
isolating a clonal population of cells that express a chimeric protein translated from said nucleic acid vector;
contacting said cells with a sample compound or composition; and
detecting the presence of cytoplasmic/nuclear translocation in response to a ligand of said ligand binding domain.

### Claim 32 (depends on 31)

The method of claim 31, wherein said marker protein domain encodes a fluorescent protein.

### Claim 33

A method for determining the concentration of a ligand of a labeled chimeric superfamily receptor protein, which comprises:
producing a nucleic acid vector encoding a nucleic acid chimera comprising: a nucleic acid sequence coding for the cytoplasmic/nuclear translocation domain of glucocorticoid receptor protein, a nucleic acid sequence coding for the ligand binding domain of a superfamily receptor protein, and a nucleic acid sequence for a marker protein domain;
transfecting a eukaryotic cell with said nucleic acid vector;
isolating a clonal population of transfected cells that express a chimeric protein translated from said nucleic acid vector;
contacting said transfected cells with a sample;
scanning one or more test cell(s) to obtain signal data from said labeled protein;
converting said signal data to obtain the cellular location of said labeled protein in said test cell(s); and
analyzing said data using an analysis system having an algorithm to calculate changes in the distribution of said labeled protein between the cell cytoplasm and the cell nucleus of said test cell(s), said analysis system having the capability of providing an accurate reading of the concentration of a ligand.

### Claim 34 (depends on 33)

The method of claim 33, wherein said marker protein domain encodes a fluorescent protein.

### Claim 35

A kit for detecting and screening for a ligand of a superfamily receptor protein in an environmental sample, comprising:
a cell-based system which expresses a chimeric protein comprising the cytoplasmic/nuclear translocation domain of glucocorticoid receptor protein, the ligand binding domain of a superfamily receptor protein, and a marker protein domain; and
a detection system for the detection of the translocation of said marker protein.

### Claim 36 (depends on 35)

The kit of claim 35, additionally comprising:
one or more compounds and/or compositions which stably associate with said chimeric protein in the absence of a ligand for the ligand binding domain of said chimeric protein, and which dissociates from said chimeric protein in the presence of a ligand for the ligand binding domain of said chimeric protein.

### Claim 37

A kit for detecting and screening for a ligand of a superfamily receptor protein in an environmental sample, comprising:
a quantity of a chimeric protein comprising the cytoplasmic/nuclear translocation domain of glucocorticoid receptor protein, the ligand binding domain of a superfamily receptor protein, and a marker protein domain;
a cell-free membrane system which restricts translocation of the chimeric protein when no ligand is bound to the ligand binding domain of said chimeric protein, and which permits translocation of the chimeric protein when the ligand binding domain of said chimeric protein is bound to its ligand; and
a detection system for the detection of the translocation of said marker protein.

### Claim 38 (depends on 37)

The kit of claim 37, additionally comprising:
one or more compounds and/or compositions which stably associate with said chimeric protein in the absence of a ligand for the ligand binding domain of said chimeric protein, and which dissociates from said chimeric protein in the presence of a ligand for the ligand binding domain of said chimeric protein.

### Claim 39

A method for diagnosis of defects in the nuclear transportation process, which comprises:
producing a nucleic acid vector encoding a nucleic acid chimera comprising: a nucleic acid sequence coding for the cytoplasmic/nuclear translocation domain of glucocorticoid receptor protein, a nucleic acid sequence coding for the ligand binding domain of a superfamily receptor protein, and a nucleic acid sequence for a marker protein domain;
transfecting a set of suspected defective cells with said nucleic acid vector;
isolating a clonal population of said cells that express a chimeric protein translated from said nucleic acid vector;
contacting said cells with a ligand of said ligand binding domain; and
detecting the presence or absence of cytoplasmic/nuclear translocation in response to said ligand.

### Claim 40

A method for treating defective translocation of a superfamily receptor protein from the cytoplasm to the nucleus of a cell, in an animal in need thereof, comprising:
producing a nucleic acid vector which is capable of being transcribed, and which encodes a nucleic acid chimera comprising: a nucleic acid sequence coding for the cytoplasmic/nuclear translocation domain of glucocorticoid receptor protein and a nucleic acid sequence coding for the ligand binding domain of said superfamily receptor protein; and
transfecting a target cell in said animal with said nucleic acid vector.

### Claim 41

A pharmaceutical composition comprising:
(i) a chimeric protein comprising two elements:
a glucocorticoid receptor 5′ end, encompassing the nuclear translocation domain and helix 1; and
a superfamily receptor 3′ end, encompassing the ligand binding domain and helix 3; and
(ii) a pharmaceutically acceptable carrier.
